Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Saracatinib - AstraZeneca

Drug Profile

Saracatinib - AstraZeneca

Alternative Names: AZD 0530; Saracatinib difumarate

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Baylor College of Medicine; Brigham and Women's Hospital; Loyola University Chicago; NHS National Services Scotland; Sheffield Teaching Hospitals NHS Foundation Trust; Stanford University; University of Cincinnati; University of Miami; University of South Florida; Yale University
  • Class Analgesics; Antidementias; Antineoplastics; Benzodioxoles; Quinazolines; Small molecules
  • Mechanism of Action Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Cancer pain; Lymphangioleiomyomatosis
  • No development reported Alcoholism
  • Discontinued Bone cancer; Breast cancer; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 12 Sep 2018 AstraZeneca in collaboration with King's College London plans a phase I trial for Parkinson's disease in United Kingdom (NCT03661125)
  • 24 Jun 2018 Biomarkers information updated
  • 28 Dec 2017 No recent reports of development identified for phase-I development in Alcoholism(In volunteers) in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top